
Symbiotec Pharmalab successfully listed on NSE and BSE on September 1, 2026 at ₹988 per share, marking the completion of its ₹1,757 crore IPO that concluded on August 27, 2026. The book-built issue comprised a fresh issue of ₹150.27 crore and offer for sale of ₹1,606.72 crore, with the company achieving 52.66 times oversubscription during the bidding period from August 24-27, 2026. The IPO was managed by JM Financial Ltd. as the book running lead manager and MUFG Intime India Pvt. Ltd. as the registrar.
According to the latest financial data, Symbiotec Pharmalab demonstrated strong operational performance with revenue increasing by 15% to ₹872.26 crore and profit after tax rising by 14% to ₹109.90 crore between March 2025 and March 2026. The company's EBITDA grew to ₹231.97 crore with a margin of 26.59%, while net worth expanded to ₹1,158.64 crore from ₹821.15 crore in the previous year. The company's PAT margin remained stable at 12.60% despite growth challenges, reflecting improved operational efficiency.
As reported by Moneycontrol, Symbiotec Pharmalab's improved earnings visibility is supported by multiple revenue streams including long-term contracts, milestone payments, and rising capacity utilisation. The company maintains global leadership in corticosteroid and steroidal hormone APIs with long-standing relationships with domestic and international customers. Its fully invested, multi-scale, vertically integrated manufacturing platform supports the pharmaceutical, nutraceutical, and wellness industries with high-quality ingredients aligned with global standards. The company's focus on research-driven manufacturing, quality compliance, and sustainable production processes positions it well for future growth.
According to Moneycontrol, the company has identified FY29 as a critical year for significant CDMO revenue accrual, reflecting its strategic shift toward higher-value manufacturing services. Symbiotec Pharmalab's improved earnings visibility is strengthened by long-term contracts, milestone payments, and rising capacity utilisation, positioning it for enhanced revenue generation in the coming years. The company's continuous investment in research and development and strong technological capabilities among Indian industry peers provide a foundation for expanding its total addressable market and developing intellectual property-driven offerings.